Logo

Fujitsu Biosciences Licenses BioMedCache Software to NeurAxon

Feb 22, 2005

NEW YORK, Feb. 22 (GenomeWeb News) - Fujitsu America's Biosciences group said today that it has licensed its BioMedCache automated docking and molecular modeling software to Canadian drug maker NeurAxon.

 

Under the terms of the agreement, NeurAxon will use the software's ActiveSite module to design small-molecule inhibitors of protein targets, Fujitsu said.

 

Financial terms of the deal were not disclosed.

Breaking News
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.